News Conference News ESC 2024 Asundexian for AF? More Details on the Sinking of OCEANIC-AF Shelley Wood September 02, 2024
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Conference News ESC 2023 FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF Shelley Wood August 28, 2023
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
Presentation ESC 2022 Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial Presenter: Sanjit Jolly August 28, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
Presentation ESC 2021 Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL Presenter: Eduardo Ramacciotti August 30, 2021
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2018 My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More Shelley Wood September 14, 2018
Presentation ESC 2018 Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results Presenter: Alex C. Spyropoulos August 27, 2018
News Conference News ESC 2018 COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure Todd Neale August 27, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018